155 related articles for article (PubMed ID: 27437103)
1. NLRC5, a promising new entry in tumor immunology.
Chelbi ST; Guarda G
J Immunother Cancer; 2016; 4():39. PubMed ID: 27437103
[TBL] [Abstract][Full Text] [Related]
2. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
3. The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.
Shukla A; Cloutier M; Appiya Santharam M; Ramanathan S; Ilangumaran S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671123
[TBL] [Abstract][Full Text] [Related]
4. NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes.
Rodriguez GM; Bobbala D; Serrano D; Mayhue M; Champagne A; Saucier C; Steimle V; Kufer TA; Menendez A; Ramanathan S; Ilangumaran S
Oncoimmunology; 2016 Jun; 5(6):e1151593. PubMed ID: 27471621
[TBL] [Abstract][Full Text] [Related]
5. Emerging Major Histocompatibility Complex Class I-Related Functions of NLRC5.
Chelbi ST; Dang AT; Guarda G
Adv Immunol; 2017; 133():89-119. PubMed ID: 28215281
[TBL] [Abstract][Full Text] [Related]
6. NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity.
Santharam MA; Shukla A; Levesque D; Kufer TA; Boisvert FM; Ramanathan S; Ilangumaran S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108368
[TBL] [Abstract][Full Text] [Related]
7. NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.
Staehli F; Ludigs K; Heinz LX; Seguín-Estévez Q; Ferrero I; Braun M; Schroder K; Rebsamen M; Tardivel A; Mattmann C; MacDonald HR; Romero P; Reith W; Guarda G; Tschopp J
J Immunol; 2012 Apr; 188(8):3820-8. PubMed ID: 22412192
[TBL] [Abstract][Full Text] [Related]
8. NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens.
Rodriguez GM; Yakubovich E; Murshed H; Maranda V; Galpin KJC; Cudmore A; Hanna AMR; Macdonald E; Ramesh S; Garson K; Vanderhyden BC
Front Immunol; 2023; 14():1295208. PubMed ID: 38235131
[TBL] [Abstract][Full Text] [Related]
9. Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I-deficient breast cancer cells.
Zhao MZ; Sun Y; Jiang XF; Liu L; Liu L; Sun LX
Immunol Res; 2019 Dec; 67(6):497-504. PubMed ID: 31900803
[TBL] [Abstract][Full Text] [Related]
10. Targeted demethylation and activation of
Sun X; Watanabe T; Oda Y; Shen W; Ahmad A; Ouda R; de Figueiredo P; Kitamura H; Tanaka S; Kobayashi KS
Proc Natl Acad Sci U S A; 2024 Feb; 121(6):e2310821121. PubMed ID: 38300873
[TBL] [Abstract][Full Text] [Related]
11. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
[TBL] [Abstract][Full Text] [Related]
12. NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner.
Neerincx A; Rodriguez GM; Steimle V; Kufer TA
J Immunol; 2012 May; 188(10):4940-50. PubMed ID: 22490867
[TBL] [Abstract][Full Text] [Related]
13. NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.
Ong CEB; Patchett AL; Darby JM; Chen J; Liu GS; Lyons AB; Woods GM; Flies AS
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1973-1991. PubMed ID: 33797607
[TBL] [Abstract][Full Text] [Related]
14. NLRC5/CITA: A Key Player in Cancer Immune Surveillance.
Yoshihama S; Vijayan S; Sidiq T; Kobayashi KS
Trends Cancer; 2017 Jan; 3(1):28-38. PubMed ID: 28718425
[TBL] [Abstract][Full Text] [Related]
15. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.
Yoshihama S; Cho SX; Yeung J; Pan X; Lizee G; Konganti K; Johnson VE; Kobayashi KS
Sci Rep; 2021 Feb; 11(1):3258. PubMed ID: 33547395
[TBL] [Abstract][Full Text] [Related]
16. NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients.
Li X; Guo F; Liu Y; Chen HJ; Wen F; Zou B; Li D; Qin Q; Liu X; Shen Y; Wang Y
Oncol Lett; 2015 Sep; 10(3):1533-1540. PubMed ID: 26622704
[TBL] [Abstract][Full Text] [Related]
17. NLRC5 potentiates anti-tumor CD8
Zhang J; Guo B; Chen JH; Liu XJ; Zhang JH; Zhu HQ; Wang WY; Tang ZH; Wei B; Cao YX; Zhan L
Transl Oncol; 2023 Oct; 36():101742. PubMed ID: 37531863
[TBL] [Abstract][Full Text] [Related]
18. Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer.
Zhan L; Zhang J; Wei B; Cao Y
Autophagy; 2022 Apr; 18(4):942-943. PubMed ID: 35174769
[TBL] [Abstract][Full Text] [Related]
19. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
Zhan L; Zhang J; Zhang J; Liu X; Zhu S; Shi Y; He Y; Wang W; Fan Y; Tang Z; Chen G; Wei B; Cao Y
Cancer Lett; 2022 Mar; 529():37-52. PubMed ID: 34974132
[TBL] [Abstract][Full Text] [Related]
20. HSP27 modulates tumoural immune evasion by enhancing STAT3-mediated upregulation of PD-L1 and NLRC5 in ovarian cancer.
Fezza M; Hilal G; Tahtouh R; Moubarak M; Atallah D
Ecancermedicalscience; 2023; 17():1526. PubMed ID: 37113720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
